---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-114926"
form_type: "8-K"
ticker: "CPRX"
cik: "0001369568"
company_name: "CATALYST PHARMACEUTICALS, INC."
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T07:23:09.342655+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# Catalyst Q1 revenues $141.4M (+43.6% YoY); GAAP EPS $0.45; reaffirms FY outlook

## Summary
- Total product revenue $141.4M, up 43.6% YoY; FIRDAPSE $83.7M (+25.3%), AGAMREE $22.0M (from $1.2M).
- GAAP net income $56.7M ($0.45 diluted EPS); Non-GAAP net income $86.6M ($0.68 diluted EPS).
- Cash and equivalents $580.7M as of March 31, 2025; no debt.
- Reaffirms full-year 2025 total revenue guidance of $545M–$565M.
- AGAMREE commercial launch momentum with 1,777.5% YoY revenue growth.

## SEC filing metadata
- accession: 0001193125-25-114926
- form_type: 8-K
- ticker: CPRX
- cik: 0001369568
- company_name: CATALYST PHARMACEUTICALS, INC.
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1369568/000119312525114926/0001193125-25-114926-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1369568/000119312525114926/d892793d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-114926
- JSON: https://secwatch.observer/filing/0001193125-25-114926.json
- Plain text: https://secwatch.observer/filing/0001193125-25-114926.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.